38,15 $
0,42 %gestern
Nasdaq, 28. März, 21:02 Uhr
ISIN
US74340E1038
Symbol
PGNY
Berichte

Progyny Inc Aktie News

Neutral
GlobeNewsWire
11 Tage alt
NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 202...
Positiv
CNBC
14 Tage alt
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
Positiv
Seeking Alpha
14 Tage alt
Progyny, Inc. (PGNY) is recommended as a buy due to its potential for continued growth and positive long-term outlook. The recent weak share price is attributed to expected weak performance in 1Q24, but this is believed to be a temporary issue. PGNY's active pipeline is the largest it has ever been, indicating future growth opportunities, particularly in the women's health vertical.
Positiv
InvestorPlace
16 Tage alt
Wagering on mid-cap stocks can potentially unlock investment treasures typically overlooked in the bustling market. Nestled between the giants and the upstarts, these stocks, with market capitalizations in the $2 billion to $10 billion range, offer a unique blend of growth potential and stability.
Neutral
GlobeNewsWire
18 Tage alt
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Michael Sturmer, Progyny's President, will participate in a fireside chat at Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024 at 10:15 A....
Positiv
Seeking Alpha
20 Tage alt
Progyny's stock is trailing the S&P 500 thus far in 2024 amongst macro concerns such as the Alabama court ruling on frozen embryos. However, Progyny's Q4 2023 revenue grew by 26%, and the company continues to add clients and increase the number of covered lives. With no debt and ample cash, the company authorized a share repurchase program up to $100 million.
Neutral
GlobeNewsWire
29 Tage alt
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100 million of its common stock. The program will be funded through available cash balances.
Negativ
Barrons
etwa ein Monat alt
Shares of fertility-solutions firm Progyny are in the red on disappointing guidance. The company says the Alabama court ruling on in vitro fertilization won't affect it.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen